A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Histologically or cytologically confirmed solid tumor by pathology report that isadvanced or metastatic

• Human Immunodeficiency Virus (HIV)-infected participants must have well controlledHIV on Antiretroviral Therapy (ART)

• Participants who are Hepatitis B Surface Antigen (HBsAg) positive are eligible ifthey have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks,and have undetectable HBV viral load before allocation

• Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCVviral load is undetectable at screening

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1or better from any Adverse Events (AEs) that were due to cancer therapeuticsadministered more than 4 weeks earlier

• History of a second malignancy, unless potentially curative treatment has beencompleted with no evidence of malignancy for 2 years

• Has clinically significant cardiovascular disease

• HIV-infected participants with a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease

• Received prior systemic anticancer therapy including investigational agents within 4weeks before the first dose of study intervention

• Has received any prior immunotherapy and was discontinued from that treatment due toa Grade 3 or higher immune-related AE (except endocrine disorders that can betreated with replacement therapy) or was discontinued from that treatment due toGrade 2 myocarditis or recurrent Grade 2 pneumonitis

• Received prior radiotherapy within 2 weeks of start of study intervention, or hasradiation-related toxicities, requiring corticosteroids

• Received a live or live-attenuated vaccine within 30 days before the first dose ofstudy intervention. Administration of killed vaccines is allowed

• Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy orany other form of immunosuppressive therapy within 7 days before the first dose ofstudy intervention

• Known additional malignancy that is progressing or has required active treatmentwithin the past 2 years

• Known active Central Nervous System (CNS) metastases and/or carcinomatous meningitis

• Active autoimmune disease that has required systemic treatment in the past 2 yearsexcept replacement therapy

• History of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease

• Active infection requiring systemic therapy

• History of allogeneic tissue/solid organ transplant

• Participants who have not adequately recovered from major surgery or have ongoingsurgical complications